Breast Cancer Research and Treatment

Article	Citations
Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach	95
Psychosocial stressors and breast cancer gene expression in the Black Women’s Health Study	72
Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up	55
Low incidence of distant metastases in older women with non-metastatic breast cancer treated with primary endocrine therapy	54
Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients	44
Comment on: sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer—results from the ABLE feasibility trial	44
L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study	42
Letter to the BRCT editor	41
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry	39
Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer	38
Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer	34
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial	34
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer	33
The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system	33
Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death	30
Intraoperative assessment of axillary sentinel lymph nodes by telepathology	29
Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer	28
Lazzaro responds to Pouwels et al.	28
Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience	27
Awareness of link between obesity and breast cancer risk is associated with willingness to participate in weight loss intervention	27
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial	27
Development of a key performance indicator for breast cancer in Queensland, Australia	27
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study	26
Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?	25
Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis	25

SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast	25
Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools	24
Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system	24
Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer	23
Letter to the editor regarding: ‘Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis’	23
Impact of body mass index on survival in women receiving chemotherapy for early breast cancer	23
The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development	23
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy	23
Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature	23
Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer	23
Clinical relevance of double heterozygosity revealed by next-generation sequencing of homologous recombination repair pathway genes in South African breast cancer patients	23
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)	22
Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study	22
Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer	22
SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast	22
Racial/ethnic and socioeconomic differences in breast cancer surgery performed and delayed treatment: mediating impact on mortality	22
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer	21
Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics	21
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study	21
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival	21
Surveillance mammography after treatment for male breast cancer	20
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry	19
Interobserver concordance in visual assessment of Ki67 immunohistochemistry in surgical excision specimens from patients with lymph node-negative breast cancer	19
Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer	19
Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting	19
The effects of exercise and diet on oxidative stress and telomere length in breast cancer survivors	19
Subspecialized breast pathologists have suboptimal interobserver agreement in Ki-67 evaluation using 20% as the cutoff	19
The association between meat and fish intake by preparation methods and breast cancer in the Carolina Breast Cancer Study (CBCS)	18
Surgical and obstetric outcomes of breast cancer surgery during pregnancy: a nationwide database study in Japan	18
Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study	18
Characteristics and risk factors of axillary lymph node metastasis of microinvasive breast cancer	18
Adherence to the 2020 American Cancer Society Guideline for Cancer Prevention and risk of breast cancer for women at increased familial and genetic risk in the Breast Cancer Family Registry: an evalua	18
Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer	18
Use of imaging prediction model for omission of axillary surgery in early-stage breast cancer patients	17
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer	17
Barrier films or dressings for the prevention of acute radiation dermatitis in breast cancer: a systematic review and network meta-analysis	17
Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients—a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy	17
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study	17
Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression	17
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer	17
The relationship between sleep and weight change among women diagnosed with breast cancer participating in the Women’s Health Initiative	17
Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast canc	17
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients	17
The largest genome-wide association study for breast cancer in Taiwanese Han population	16
Analysing potent biomarkers along phytochemicals for breast cancer therapy: an in silico approach	16
Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients	16
Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression	16
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?	16
Serum hormone levels and normal breast histology among premenopausal women	16
The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)	16

Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study	16
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis	16
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia	16
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer	15
BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance	15
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers	15
Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience	15
The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery	15
DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS	15
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform	15
Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer	14
The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer	14
Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis	14
Comparison of partial-breast irradiation and intraoperative radiation to whole-breast irradiation in early-stage breast cancer patients: a Kaplan-Meier-derived patient data meta-analysis	14
Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis”	14
Radiotherapy, chemotherapy, and heart disease	14
Polycystic ovary syndrome and risk of breast cancer in premenopausal and postmenopausal women: a nationwide population-based cohort study	14
Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors	14
Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants	14
Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer	14
Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy	14
A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer	14
STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression	14
Comments on the effects of exercise and diet on oxidative stress and telomere length in breast cancer survivors	14
Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated	13
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde	13
The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study	13
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer	13
Pro-vegetarian dietary pattern and risk of breast cancer: a case–control study	13
Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience	13
A retrospective study in tumour characteristics and clinical outcomes of overweight and obese women with breast cancer	13
Integrated analysis of diverse cancer types reveals a breast cancer-specific serum miRNA biomarker through relative expression orderings analysis	13
Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???	13
ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells	13
Metastatic pure invasive lobular breast cancer or metastatic mixed invasive ductal and lobular breast cancer: are they different entities?	13
Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study	13
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis	13
Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer	13
Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients	13
Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer	13
Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study	13
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study	12
Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy	12
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience	12
Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer	12
Evaluation of online Spanish and English health materials for preventive mastectomy. are we providing adequate information?	12
Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer	12
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy	12
Should low-risk DCIS lose the cancer label? An evidence review	12
Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis	12
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventi	12
Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO	12
Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews	12
Is there an association between endometriosis and subsequent breast cancer? A retrospective cohort study from Germany	12
Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery	12
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study	11
Breast cancer treatment patterns by age and time since last pregnancy in the Carolina Breast Cancer Study Phase III	11
Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system	11
HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity	11
Cardiotoxicity among socioeconomically marginalized breast cancer patients	11
Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients	11
Routine and interval detection of locoregional breast cancer recurrences and risk of subsequent distant metastasis	11
Impact of age, race, and family history on COVID-19–related changes in breast cancer screening among the Boston mammography cohort study	11
The clinical relevance of various methods of classifying ipsilateral breast tumour recurrence as either true local recurrence or new primary	11
Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation	11
Women with metastatic breast cancer don't just follow step-count trends, they exceed them: an exploratory study	11
Use of endocrine therapy for estrogen receptor-positive breast cancer among American Indians and Alaska natives	11
Sleep medication use and risk of fractures in breast cancer survivors	11
Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer	11
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis	11
Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period	11
HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines	11
Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA	11
Barriers and engagement in breast cancer survivorship wellness activities	11
Endocrine adherence in male versus female breast cancer: a seer-medicare review	11
Clever-1 positive macrophages in breast cancer	11
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging	11
A web-based personalized decision support tool for patients diagnosed with ductal carcinoma in situ: development, content evaluation, and usability testing	11
Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy	11
Breast cancer in Colombia: a growing challenge for the healthcare system	11

The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer	10
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study	10
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients	10
Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up	10
Evaluation of SNPs associated with mammographic density in European women with mammographic density in Asian women from South-East Asia	10
Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer	10
Immunotherapy toxicity: identification and management	10
Survival outcomes for breast conserving surgery versus mastectomy among elderly women with breast cancer	10
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy	10
Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer	10
Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database	10
Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy	10
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer	10
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials	10
Impact of axillary surgery on outcome of clinically node positive breast cancer treated with neoadjuvant chemotherapy	10
Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer	10
Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database	10
Management and outcomes of men diagnosed with primary breast cancer	10
Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers	10
The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa	10
Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer	10
Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase	10
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer	10
Retraction Note: Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin	10
Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer	10
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA3	10
Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation	10
Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy	10
Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000–2016	10
Trends in surgery and adjuvant treatment for early-stage breast cancer: a population-based study in Queensland, Australia	10
Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors	9
COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation	9
Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis	9
Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study	9
Quantitative analysis of pressure levels in manual lymphatic drainage across stages of breast cancer-related lymphedema: implications for optimized treatment protocols	9
Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study	9
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review	9
Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression	9
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients	9
Early experience of robotic axillary lymph node dissection in patients with node-positive breast cancer	9
Feasibility of introducing a smartphone navigation application into the care of breast cancer patients (The FIONA Study)	9
Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients	9
Does the toxicity of endocrine therapy persist into long-term survivorship?: Patient-reported outcome results from a follow-up study beyond a 10-year-survival	9
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor	9
Effect of neighborhood deprivation index on breast cancer survival in the United States	9
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation	9
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature	9
Advances in the prevention and treatment of breast cancer-related lymphedema	9
Breast reconstruction and quality of life five years after cancer diagnosis: VICAN French National cohort	9
Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer	9
Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care	9
Phenotypes of carriers of two mutated alleles in major cancer susceptibility genes	9
EGFR as a potent CAR T target in triple negative breast cancer brain metastases	9
Diagnostic value of alkaline phosphatase and bone-specific alkaline phosphatase for metastases in breast cancer: a systematic review and meta-analysis	9
Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic	9
Application of genetic testing criteria for hereditary breast cancer in South Africa	9
Demographic and clinical trends of young breast cancer patients from the national cancer database: disproportionate effect on minority populations	9
Letter to the editor: “Frequency of zoledronate administration in early breast cancer”	9
The WISDOM study: a new approach to screening can and should be tested	9
MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975	9
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer	9
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study	9
Textbook outcomes in DIEP flap breast reconstruction: a Delphi study to establish consensus	9
Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers	9
De-ESCAlating RadioTherapy in breast cancer patients with pathologic complete response to neoadjuvant systemic therapy: DESCARTES study	9
Classes of therapeutics to amplify the immune response	8
Retraction Note to: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression	8
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe	8
Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS	8
Investigating the role of core needle biopsy in evaluating tumor-stroma ratio (TSR) of invasive breast cancer: a retrospective study	8
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlle	8
Mammography use and breast cancer incidence among older U.S. women	8
Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?	8
Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN	8
Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study	8
Prognostic and predictive impact of NOTCH1 in early breast cancer	8
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy	8
Response to letter “re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: A nationwide population–based retrospective cohort study in Belgium and the National Cancer Data	8
Risk-reducing surgeries for breast cancer in Brazilian patients undergoing multigene germline panel: impact of results on decision making	8
Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer	8
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies	8
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in rea	8
Factors associated with late risks of breast cancer-specific mortality in the SEER registry	8
Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study	8
Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine	8
Head-to-head comparison of contrast-enhanced mammography and contrast-enhanced MRI for assessing pathological complete response to neoadjuvant therapy in patients with breast cancer: a meta-analysis	8
Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression	8
Triaging mammography with artificial intelligence: an implementation study	8
Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history	8
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer	8
Clinical characteristics and prognosis of postpartum breast cancer	8
Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer	8
A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients	8
New horizons in imaging and surgical assessment of breast cancer lymph node metastasis	8
Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers	8